Simcere Pharmaceutical Group (FRA:S2P) Quality Rank

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:S2P Simcere Pharmaceutical Group Ltd FRA:S2P
86 GF Score
Price €1.36
GF Value €1.15
Valuation Modestly Overvalued
View Full Analysis

What is Simcere Pharmaceutical Group Quality Rank?

The Quality Rank measures the business quality of a company relative to other companies. It is ranked based on the strength of the balance sheet, as well as the profitability and growth of the business. The ranked companies are split in equal numbers and then ranked from 1 to 10, with 10 being the highest.

The rank of balance sheet (30%)

The rank of balance sheet is done through the ranking of:
  • Interest coverage
  • Zscore
  • Debt to revenue
  • Equity to asset
  • Cash to debt

The rank of Profitability (70%)

The ranking of Profitability is done by ranking:
  • Operating margin mean rank (10-year mean average profit margine)
  • Operating margin growth rank
  • Fscore
  • Predictability rank
  • Revenue growth rank (5 year), when the growth is higher than 25%, set it as 25%
  • Num of year profit (number of years that is profitable within the last 10 years)
  • ROIC median (10-year median of ROIC)

Simcere Pharmaceutical Group Quality Rank Related Terms

FRA:S2P
86GF Score
Simcere Pharmaceutical Group Ltd FRA:S2P
Quality Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Simcere Pharmaceutical Group (FRA:S2P) Overvalued in 2026?

Based on GuruFocus' analysis, Simcere Pharmaceutical Group stock appears to be overvalued. The current stock price of €1.36 is trading 18.3% above its estimated GF Value™ of €1.15. GuruFocus considers Simcere Pharmaceutical Group to be Modestly Overvalued.

Key valuation signals for FRA:S2P:

  • Quality Rank:
  • GF Value™: €1.15 vs. price of €1.36 (18.3% above fair value)
  • GF Score™: 86/100

No single metric tells the full story. See the FRA:S2P stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Simcere Pharmaceutical Group Business Description

Other Exchanges 02096:Hong KongS2P:Germany
Address No. 699-18, Xuanwu Road, Xuanwu District, Jiangsu Province, Nanjing, CHN, 210042
Simcere Pharmaceutical Group Ltd is engaged in the R&D, production, and commercialization of pharmaceuticals focused on generic pharmaceuticals. The company has a diversified product portfolio focused on therapeutic areas, including, neuroscience, anti-oncology, autoimmune, and antiinfection. The company's products include Endostar, Enweida, Enzeshu, Iremod, Quviviq, Cosela, Sanbexin and Others.
86GF Score

Get the complete analysis for FRA:S2P

Quality Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.36
Price
€1.15
GF Value